LAIR1

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need

Retrieved on: 
Tuesday, January 9, 2024
Bile, Woman, Hyperemesis gravidarum, Research, Biology, Hospital, Weight loss, MSS, FRS, Hepatology, University, ILT3, Liver disease, FGF19, GFRAL, LAIR1, Liver, Doctor of Philosophy, NASH, CRC, Pembrolizumab, Trial of the century, Neoplasm, NGM, SAN, PRS, Public health, Genetic epidemiology, Preterm birth, Vomiting, Cirrhosis, DCR, Dehydration, AASLD, Immunotherapy, Place of birth, Medicine, Pregnancy, Pre-eclampsia, Therapy, ELF, Patient, Bile acid malabsorption, Fibrosis, Nausea, Alkaline phosphatase, PSC, Gastrointestinal disease, CRN, IBS-D, Malnutrition, FDA, Biomarker, Pharmaceutical industry

NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.

Key Points: 
  • NGM Bio also outlined its strategy to evolve clinical development of its product candidates aldafermin and NGM120 to focus on rare conditions characterized by significant unmet need.
  • Recent landmark genetic research confirmed the link between this rare, devastating condition experienced during pregnancy to higher levels of GDF15.
  • Given our deep expertise in GDF15 biology, we believe we are well positioned to potentially pursue this indication for NGM120.
  • NGM Bio previously reported data from a randomized, double-blind, placebo-controlled Phase 2 study of aldafermin for the treatment of PSC.

NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Thursday, November 2, 2023
Research, LAIR1, PwC, Therapy, Biotechnology, Pembrolizumab, Cirrhosis, Liver, VaxGen, F4, ILT3, NASH, LLP, NGM, Part, CFO, Cancer, Patient, AASLD, Toxic leukoencephalopathy, Medical imaging, Pharmaceutical industry, Merck

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended September 30, 2023 and provided business highlights. 

Key Points: 
  • “In the third quarter, we continued to advance our efforts to develop novel medicines for cancer and other grievous diseases.
  • This includes steady progress across our clinical-stage solid tumor oncology portfolio,” said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM Bio.
  • NGM Bio reported a net loss of $28.8 million for the quarter ended September 30, 2023, compared to a net loss of $47.3 million for the same period in 2022.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into mid-2025.

NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Thursday, August 3, 2023
BAM, Gastrointestinal disease, IBS-D, Therapy, NASH, ILT3, G&A, LAIR1, ELF, Patient, SAN, NGM, Pembrolizumab, Cirrhosis, Safety, Medical imaging, Pharmaceutical industry, Rare-earth element, Merck

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today reported financial results for the quarterly period ended June 30, 2023 and provided business highlights. 

Key Points: 
  • Announced Siobhan Nolan Mangini will step down as President and Chief Financial Officer at NGM Bio.
  • NGM Bio incurred restructuring charges of approximately $5.0 million, the majority of which were paid in the second quarter.
  • NGM Bio reported a net loss of $38.3 million for the quarter ended June 30, 2023, compared to a net loss of $46.5 million for the same period in 2022.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into the second quarter of 2025.

NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data

Retrieved on: 
Thursday, May 4, 2023
Therapy, NASH, ILT3, FGF19, LAIR1, ELF, Fibrosis, Development, Patient, NGM, Health, Research, Pembrolizumab, Cirrhosis, Safety, Medical imaging, Management, Pharmaceutical industry, Cryptocurrency, Merck

“We are pleased with the results of the ALPINE 4 trial supporting the therapeutic potential of aldafermin in patients with advanced NASH.

Key Points: 
  • “We are pleased with the results of the ALPINE 4 trial supporting the therapeutic potential of aldafermin in patients with advanced NASH.
  • Jin-Long Chen, Ph.D., who founded NGM Bio and served as Chief Scientific Officer and as a member of NGM Bio’s Board of Directors, resigned from NGM Bio effective April 4, 2023.
  • NGM Bio expects to incur approximately $5.0 million in charges in connection with the restructuring, the majority to be incurred in the second quarter.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into the second quarter of 2025.

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Congress, Safety, ESMO, FGF19, C3, Week, European Society for Medical Oncology, LAIR1, ILT3, Research, Multiple myeloma, NGM, Merck & Co., Drug discovery, Patient, R, ASH, Geographic atrophy, Therapy, SAN, NASH, GA, AML, CD3, Society, Macular degeneration, Pharmaceutical industry, Cryptocurrency, Merck

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the fourth quarter and full year ended December 31, 2022.
  • Preliminary findings indicated that NGM707 was generally well tolerated across all dose levels and demonstrated early signals of anti-tumor activity across multiple tumor types.
  • NGM Bio reported a net loss of $36.4 million and $162.7 million for the quarter and year ended December 31, 2022, respectively, compared to a net loss of $27.2 million and $120.3 million for the same periods in 2021.
  • Cash, cash equivalents and short-term marketable securities were $271.5 million as of December 31, 2022, compared to $366.3 million as of December 31, 2021.

NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities

Retrieved on: 
Monday, January 9, 2023
Congress, Merck, Retina, AML, GFRAL, Multiple myeloma, NGM, Geographic atrophy, Safety, ILT3, C3, FGF19, ASH, LAIR1, Conference, GDF15, Week, ESMO, AACR, Therapy, Patient, Drug discovery, Macular degeneration, European Society for Medical Oncology, Cancer, SAN, Society, Pancreatic cancer, NASH, Pembrolizumab, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine

“In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.

Key Points: 
  • “In 2022, NGM Bio sharpened its focus on oncology solid-tumor clinical development.
  • Dr. Woodhouse continued, “Our strategy in 2023 is to focus our clinical development efforts on our portfolio of four clinical-stage oncology programs while operating our prolific drug discovery engine to generate next-generation biologic therapeutics.
  • For our programs outside this area of focus, in retinal disease and NASH, we will seek development partners with relevant domain expertise.
  • Presented additional findings from post-hoc analyses from the CATALINA trial at The Retina Society Annual Scientific Meeting in Q4 2022.

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

Retrieved on: 
Wednesday, December 7, 2022
Neoplasm, Retina, RO, PR, COVID-19, Pneumonitis, Liver, Tumor microenvironment, Health, Safety, Congress, Cancer, European Society for Medical Oncology, Protein engineering, ILT3, ILT2, GFRAL, Trae tha Truth, Biology, Therapy, LIR, Merck, LILRB4, ILT, RECIST, Translation, Oncology, Disease, Patient, ILT4, ESMO, Linearity, Cell, Failure, LAIR1, NGM, Myelocyte, G5, Merck Sharp & Dohme Federal Credit Union, Part, CD163, Merck & Co., Risk, Pharmaceutical industry, Vaccine

The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).

Key Points: 
  • The Phase 1 portion of the ongoing NGM707 trial includes a monotherapy dose escalation arm (Part 1a) and a dose-finding arm in combination with pembrolizumab (KEYTRUDA®) (Part 1b).
  • The Phase 2 portion of the trial will include expansion cohorts of patients treated with NGM707 in combination with KEYTRUDA (Part 2b) in several advanced solid tumor types.
  • The Part 1a arm enrolled patients into escalating NGM707 dose cohorts (6 mg to 1800 mg) administered intravenously every three weeks.
  • As of a November 23, 2022 data cut-off, 34 patients have been enrolled in the monotherapy dose escalation.

Immune-Onc Therapeutics Appoints Two New Members to its Board of Directors

Retrieved on: 
Tuesday, November 8, 2022
Biotechnology, Pharmaceutical, Health, Oncology, National, LILRB4, LAIR1, LILRB2, White blood cell, Industry, Onyx Pharmaceuticals, Case Western Reserve University, Patient, Lymphatic system, Doctor of Philosophy, ILT4, GSK, NCI, Board, Leukemia & Lymphoma Society, Cancer, Immunotherapy, California Institute for Quantitative Biosciences, Chronic myelomonocytic leukemia, Regenerative medicine, University of California, Davis, UCSF, California Institute for Regenerative Medicine, Drug development, University, CIRM, National Cancer Institute, NIH, Board of directors, University of California, San Francisco, OncoMed, Leadership, Genentech, Medicine, Amgen, Record, Leukemia, Biology, Acute myeloid leukemia, BeiGene, LLS, Research, Therapy, Tumor microenvironment, AML, CMML, ILT3, Regeneron Pharmaceuticals, Cytokine, Vaccine, Pharmaceutical industry

"Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.

Key Points: 
  • "Austin and Barbara have a deep understanding of the discovery and development process for breakthrough cancer therapies, experience that both complements and expands the expertise of our Board.
  • Immune-Oncs pioneering role in developing myeloid checkpoint inhibitors as next generation immunotherapies has impressed me, said Dr. Gurney.
  • Austin Gurney, Ph.D. is a biotech industry veteran with over two decades of experience in the discovery and development of novel therapeutics.
  • Immune-Oncs focused platform approach has led to the development of several promising therapeutics across various stages of development.

NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
MSD, Private Securities Litigation Reform Act, GDF15, Biology, FGF19, Bias, GFRAL, Failure, U.S. Securities and Exchange Commission, Disease, SEC, SAN, Congress, GLOBE, Fatty liver disease, Retina, NGM, Health, Geographic atrophy, Prostate cancer, Patient, Cancer, Protein engineering, Research, ILT3, Merck & Co., COVID-19, Pancreatic cancer, Cirrhosis, Therapy, LAIR1, NASH, Conference, Nasdaq, Risk, Merck Sharp & Dohme Federal Credit Union, Pembrolizumab, AACR, Liver, Pharmaceutical industry, Medical imaging, Merck

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a clinical-stage biotechnology company focused on discovering and developing transformative therapeutics for patients, today provided business highlights and reported financial results for the quarterly period ended September 30, 2022. 

Key Points: 
  • MK-3655 is an agonistic antibody product candidate binding to fibroblast growth factor receptor 1c-beta-klotho that Merck licensed from NGM Bio.
  • NGM Bio reported a net loss of $47.3million for the quarter ended September30, 2022, compared to a net loss of $28.9 million for the same period in 2021.
  • R&D expenses were $46.1million for the quarter ended September30, 2022, compared to $38.7million for the same period in 2021.
  • NGM Bio expects its cash, cash equivalents and marketable securities will be sufficient to fund its planned operations into the fourth quarter of 2024.